ABSTRACT
Familial Mediterranean fever (FMF) is the most common hereditary auto-inflammatory disease, characterized by self-limited fever and serositis. 1 FMF is an autosomal recessive disease mainly affecting Middle-East populations such as Turks, Jews, Arabs, Armenians and other ethnic groups living around the Mediterranean basis like Italians, Greek and Druze. In the Middle-East region, the prevalence of FMF is 1/200-1000 with a high carrier rate of 1/3-5. [2] [3] [4] [5] The MEditerranean FeVer gene located on chromosome 16 encodes a protein called 'pyrin'/'marenostin'. Pyrin plays a pivotal role in the regulation of both inflammation and apoptosis. 6, 7 FMF is characterized by febrile episodes caused by recurrent auto-inflammation accompanied by signs of serositis such as peritonitis, pleuritis, synovitis and sometimes additional clinical findings of erysipelas-like erythema and acute scrotum attacks. Between these attacks, patients are usually asymptomatic. L-Carnitine ( LC; b-hydroxy-ytrimethylaminobutyric acid) is an important molecule in human metabolism, especially for the mitochondrial oxidation of fatty acids. Carnitine can be synthesized endogenously from essential amino acids; lysine and methionine. 8 Animal products like meat, fish, poultry, and milk are the best sources for dietary carnitine and they provide 75% of the daily requirements. 9 Carnitine deficiencies are divided into two categories, primary carnitine deficiency and secondary carnitine deficiency (SCD). Primary carnitine deficiency is a rare autosomal recessive inherited disorder of fatty acid oxidation caused by deficiency of plasma membrane carnitine transport resulting from defective plasma membrane carnitine/organic cation transporter 2 activity. 10, 11 SCD is related with some inherited metabolic disorders; treatment with some drugs like valproate, zidovudine and pivampicilin. [12] [13] [14] [15] [16] SCD could be also associated with chronic conditions including kidney disease, diabetes mellitus, heart failure, cirrhosis, malabsorption, and Alzheimer disease. [17] [18] [19] [20] [21] Trauma, sepsis and acute organ failure result in increased needs of carnitine; therefore, may cause SCD. 8, [22] [23] [24] To our knowledge, no study has been conducted documenting free carnitine (FC) and acylcarnitine (AC) esters in FMF patients. Our hypothesis was that FMF patients might have lower FC levels than an age and sex matched healthy control group due to increased need of carnitine because of recurrent auto-inflammation. Thus, in this study, we aimed to demonstrate the patterns of FC and AC esters in FMF patients. A fasting blood sample was taken for FC and AC esters with quadrupole electrospray ionization mass spectrometry-mass spectrometry from children in both groups. Samples consisted of capillary blood were collected on Whatmann S&S 903 filter paper (Sigma-Aldrich, St. Louis MO, USA). The sampling was done by finger prick. Samples were dried in room temperature. Relevant AC butyl esters were extracted and derivatized from 1/3 inch dried blood samples and were analyzed using a protocol described by Schulze et al. 25 previously. AC butyl esters were detected due to mass/ion ratios with electrospray ionization mass spectrometry-mass spectrometry. Agilent 1200 series auto sampler (Agilent, Waldbronn, Germany) and Water Micromass Quattro LC Likrom™ tandem mass spectrometry (Waters, Manchester, England) were used for the analyses. AC was screened by positive ion mode m/z 85 parents screening function. The quantitative values of signal intensities were calculated using MassLynx and NeoLynx softwares (Version 4.1). Both signal intensities and calculated concentrations were exported to spreadsheet software where flagging abnormal concentrations and further evaluations were done. 25, 26 The study was reviewed and approved by the Ethics Committee of ‹stanbul University Cerrahpaa Medical Faculty. Signed informed consent was obtained from parents of all patients' who participated in the study. The investigation conforms to the principles outlined in the Declaration of Helsinki.
PATIENTS AND METHODS

Statistical analysis
Data were expressed using descriptive statistics such as mean and standard deviation for continuous variables and number and percentage for categorical variables. A one-sample t-test was carried out for the quantitative estimation of AC analyses. Comparison between the groups was carried out by independent sample t-test. Statistical analyses were done with IBM SPSS Statistics version 21.0 (IBM Corporation, Armonk, NY, USA). P value <0.05 was considered statistically significant.
RESULTS
Patients' clinical and demographic characteristics were given in Table 1 . AC analyses in spot dried blood samples with electrospray ionization mass spectrometry-mass spectrometry were performed in patient and control groups. Screening of AC profile revealed increased FC (p<0.001), 3-hydroxypalmitoylcarnitine (C16-OH) (p<0.05) and 3-Hydroxy butyrylcarnitine (C4-OH) and 3-Hydroxy octadecanoylcarnitine (C18:2-OH) (p<0.05) carnitine levels, while decreased acetyl-carnitine (C2) (p<0.001), propionyl-carnitine (C3) (p<0.001), butyryl-carnitine (C4) (p<0.001), tiglyl-carnitine (C5:1) (p<0.05), hexanoyl-carnitine (C6) (p<0.001), octanoyl-carnitine (C8) (p<0.05), decenoylcarnitine (C10:1) (p<0.001), decadienoylcarnitine (C10:2) (p<0.05), malonylcarnitine (C3DC) (p<0.05), methylmalonylcarnitine (C4DC) (p<0.001), glutarylcarnitine (C5DC) (p<0.001), hexadecenoylcarnitine (C16:1) (p<0.05), 3-Hydroxy butyrylcarnitine (C4-OH) (p<0.001), 3-Hydroxy oleylcarnitine (C18:1-OH) (p<0.01) carnitine levels in FMF patients than the control group.
Total AC levels (p<0.001) and AC to FC ratio (p<0.001) were lower in FMF patients than the controls. The AC profile of the groups was listed in Table 2 .
DISCUSSION
In this study, we evaluated FC and AC levels by using tandem mass spectrometry in FMF patients. To our knowledge, this is the first report regarding the carnitine status of FMF patients. Cellular energy metabolism is largely based on mitochondrial b-oxidation of fatty acids, especially after prolonged fasting or exercise when carbohydrate stores are depleted. Carnitine plays an important role in esterification of long chain fatty acid and transport through to mitochondria for b-oxidation and ATP generation. Carnitine also stimulates pyruvate dehydrogenase complex activity, the Krebs cycle and increasing branchedchain amino acid oxidation in muscle. 27, 28 In addition, neuroprotective and anti-oxidant effects of carnitine have been shown in various studies. [29] [30] [31] Our hypothesis was that individuals with FMF would have lower FC levels than their healthy age and sex matched controls due to increased need of carnitine because of recurrent auto-inflammation; however, neither carnitine deficiency nor decreased FC levels compared to the healthy controls were detected in the study.
Conversely; FC, C16:OH and C18:2 levels were higher in children with FMF. In FMF patients; C2, C3, C4, C5:1, C6, C8, C10:1, C10:2, C3DC, C4DC, C5DC, C18:1-OH carnitine levels were lower than controls. Studies suggest that acyl to FC ratio >0.4 might be an evidence for carnitine deficiency. On the other hand, total AC levels and acyl to FC levels were also lower in FMF patients than control group. In our study, neither FMF All of the patients in this study were under treatment of colchicine which is a well-known anti-mitotic drug that decreases leucocyte phagocytosis and motility in inflammatory responses. 32 None of our FMF patients were resistant to colchicine treatment although previous studies suggested that 10% to 15% of FMF patients have resistance to colchicine treatment. 33, 34 Well-controlled disease with colchicine treatment might have resulted in suppression of the auto-inflammation, thus the need of carnitine. Also, insidious skeletal muscle damage might have resulted in elevated FC levels in FMF patients. 35 In conclusion, usage of carnitine in all patients with FMF is not recommended since we were unable to demonstrate SCD in FMF patients in the present study. Further studies screening carnitine status in acute FMF attacks are needed to explore the carnitine profile in FMF patients and highlight the efficacy and necessity of L-carnitine therapies.
